IXICO draws 104% upside estimate from Cavendish as tools expand
Published: 21:15 19 Nov 2026 AEDT
IXICO PLC (LSE:IXI, OTC:PHYOF) imaging platform upgrade and two technology partnerships support its licensing plans, according to corporate broker Cavendish, which kept its ‘buy’ rating and 26.0p price target.
The broker put the implied upside at 104% and kept its forecast for a 2026 adjusted loss of 1.4p per share.
Cavendish expects Ixico’s revenue to rise from £8.0 million in the 2026 financial year to £9.0 million in 2027, with the adjusted EBITDA loss widening from £1.7 million to £2.4 million.
Cavendish sees commercial potential in the latest IXI Platform release, which makes it easier to integrate partners’ technology and improves image quality control for customers running clinical trials.
Two partnerships broaden what customers can access through the platform, with Neuropacs providing an algorithm to help distinguish Parkinson’s disease and ZRO Imaging extending PET imaging capabilities for Alzheimer’s and other neurodegenerative disorders.
The broker sees easier integration as a way to generate recurring, high-margin licensing revenue alongside the company’s established clinical trial imaging services.
Alongside the tools supplied by its partners, Ixico is developing its own imaging technology and said on 17 November that its new AI tool could detect about 90% of cerebral microbleeds in each MRI scan.
These microbleeds are an important safety signal in patients with Alzheimer’s, particularly those receiving anti-amyloid treatments, and the company believes its tool could make detection more accurate and consistent.